(*Azadirachta indica* PLA_2 inhibitor), BMS-181162, LY311727, ARL-67974, FPL67047, SB-203347, Ro-23-9358, YM-26734, YM 26567, IS-741, MJ33, flunixin, Effipladib, Way 196025, Ecopladib, Giripladib, Variabilin, SB 203347, PAF-AH, Darapladib, phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), and phosphatidylglycerol (PG) and mixtures thereof.

103. Use according to claim 102, wherein said PLA_2 inhibitor is selected from the group consisting of phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), and phosphatidylglycerol (PG) and mixtures thereof conjugated to at least one compound selected from the group consisting of carboxymethylcellulose (CMPE, CMC-Peor CME), hyaluronic acid (HYPE, HyPE, and Hyal-PE), heparin (HEPPE, HepPE, HePPE, Hepa-PE), chondroitine sulfate A (CSAPE, CsaPE, CsAPE), Polygeline (haemaccel) (HemPE, HEMPE), hydroxyethylstarch (HesPE, HESPE)(preferably Hyaluronic acid-linked phosphatidyl ethanolamine (HyPE)) and mixtures, pharmaceutically acceptable salts, enantiomers, diastereomers, solvates and polymorphs thereof.

104. Use according to any of claims 99-103, wherein the metalloproteinase inhibitor and PLA_2 inhibitor are administered intravenously, intramuscularly or orally to the subject (1) at a concentration of between about 1 to about 1200µM; and/or (2) in an amount of between about 0.001 and 1,000 mg, or in an amount of between about 1 and about 100 g, and wherein the concentration of the metalloproteinase inhibitor and PLA_2 inhibitor can be the same or different.

105. Use according to any of claims 99-104, wherein the metalloproteinase inhibitor is prinomastat, vorinostat, BB-94 (marimastat), BB-2516 (batimastat), nafamostat, ilomastat, doxycycline, tanomastat and the PLA_2 inhibitor is selected from the group consisting of varespladib, N,N-dimethylcarbamoylmethyl,4-4-guanidinobenzoyloxy-phenylacetate (camostate), and ethyl-p[6-guanidinohexanoyloxy]-benzoate methansulfonate (gabexate).

106. Use according to claim 102, wherein the metalloproteinase inhibitor, PLA_2 inhibitor and/or serine protease inhibitor are administered to the subject topically or transdermally at the site of envenomation.

107. Use according to claim 104, wherein the metalloproteinase inhibitor, PLA_2 inhibitor, serine protease inhibitor, acetylcholinesterase inhibitor, and/or antibiotic, spreading factor inhibitor and NMDA antagonist are administered to the subject in the form of a paste or gel.

108. Use according to any of claims 79-107, wherein the subject suffers from envenomation believed to be attributable to a bite from a snake.

109. Use according to any of claims 79-107, wherein the subject's envenomation is the result of a snakebite.

110. Use of an effective dose of a PLA2 inhibitor in the manufacture of a medicament for treating envenomenation in a patient or subject in need wherein reversal or reduction of signs and symptoms of envenomation in said patient or subject is evident within about 5 minutes to no more than 30 minutes after administration of said PLA2 inhibitor.

111. Use according to claim 110 wherein said PLA2 inhibitor is administered in combination with at least one additional agent selected from the group consisting of a metalloproteinase inhibitor, a serine protease inhibitor or a mixture thereof wherein the PLA2 inhibitor and the additional agent(s) is administered to said patient or subject separately or as a mixture in a single medicament.

112. A composition comprising an effective amount of at least one antivenom in combination with an effective amount of at least one compound selected from the group consisting of a PLA2 inhibitor, a Metalloproteinase inhibitor and a Serine Proteinase inhibitor.

113. The composition according to claim 112, wherein the at least one antivenom is combined with at least one compound selected from the group consisting of varespladib, methylvarespladib, indoxam, methylindoxam, prinomstat, marimastat, batimastat, voirinostat, camostat and gabexate or a pharmaceutically acceptable salt thereof.

114. The composition according to claim 113 comprising said at least one antivenom and at least varespladib, methylvarespladib, indoxam, methylindoxam or a pharmaceutically acceptable salt thereof.

115. The composition according to claim 113, wherein said at least one antivenom is combined with varespladib and/or methylvarespladib or a pharmaceutically acceptable salt thereof.

116. The composition according to any of claims 111-115 wherein said antivenom is CroFab® and/or Anavip® Crotalinae.

117. The composition according to any of claims 111-116 in two parts, the first part of said composition comprising said at least one compound in parenteral, intranasal, ocular, oral, topical or inhalation dosage form and the second part of said composition comprising said antivenom in parenteral, intranasal, ocular, oral, topical or inhalation dosage form.

118. The composition according to any of claims 111-116 formulated in a single part in parenteral, intranasal, ocular, oral, topical or inhalation dosage form.

119. A method of treating an envenomation in a patient or subject in need comprising coadministering to said patient or subject an effective amount of at least one antivenom in combination with an effective amount of at least one compound selected from the group consisting of a PLA2 inhibitor, a Metalloproteinase inhibitor and a Serine Proteinase inhibitor.

120. The method according to claim 119, wherein the at least one antivenom is coadministered with at least one compound selected from the group consisting of varespladib, methylvarespladib, indoxam, methylindoxam, prinomstat, marimastat, batimastat, vorinostat, camostat and gabexate or a pharmaceutically acceptable salt thereof.

121. The method according to claim 120 comprising coadministering at least one antivenom and at least one of varespladib, methylvarespladib, indoxam, methylindoxam or a pharmaceutically acceptable salt thereof.

122. The method according to claim 121, comprising coadministering at least one antivenom with varespladib or a pharmaceutically acceptable salt thereof.

123. The method according to any of claims 118-122 wherein said antivenom comprises at least CroFab®.

124. The method according to any of claim 118-122 wherein said antivenom is CroFab® and/or Anavip® Crotalinae.